Please select the option that best describes you:
In general, how do you manage patients with early-stage endometrioid endometrial cancer who have concomitant POLE and TP53 mutations?
Is there enough evidence to presume these cancers have the favorable prognosis seen with other POLE-mutated tumors? Do you alter your treatment recommendations from what they would otherwise be if someone has both of these mutations?
Answer from: Radiation Oncologist at Community Practice
Based on published outcome data, double mutation is uncommon, and the outcome is driven by the better of the two mutations. So in the above situations, POLE type and not TP53 type will drive outcome and treatment decisions. That’s why in molecular-based decisions, it is important that the POLE...
Sign in or Register to read more